pI: 7.4609 |
Length (AA): 361 |
MW (Da): 41098 |
Paralog Number:
4
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_129442)
Species | Accession | Gene Product |
---|---|---|
Babesia bovis | BBOV_IV010480 | mitogen activated protein kinase, putative |
Caenorhabditis elegans | CELE_C05D10.2 | Protein C05D10.2, isoform B |
Cryptosporidium hominis | Chro.20213 | mitogen-activated protein kinase 1, serine/threonine protein kinase |
Cryptosporidium parvum | cgd2_1960 | mitogen-activated protein kinase 1, serine/threonine protein kinase, putative |
Dictyostelium discoideum | DDB_G0283903 | ERK subfamily protein kinase |
Drosophila melanogaster | Dmel_CG32703 | Extracellularly regulated kinase 7 |
Echinococcus granulosus | EgrG_000676200 | mitogen activated protein kinase 15 |
Entamoeba histolytica | EHI_073650 | mitogen-activated protein kinase |
Echinococcus multilocularis | EmuJ_000676200 | mitogen activated protein kinase 15 |
Giardia lamblia | GL50803_22850 | Kinase, CMGC MAPK |
Homo sapiens | ENSG00000181085 | mitogen-activated protein kinase 15 |
Leishmania braziliensis | LbrM.35.0840 | protein kinase, putative,mitogen-activated protein kinase, putative |
Leishmania donovani | LdBPK_360780.1 | mitogen-activated protein kinase 2 |
Leishmania infantum | LinJ.36.0780 | protein kinase, putative,mitogen-activated protein kinase, putative |
Leishmania major | LmjF.36.0720 | protein kinase, putative,mitogen-activated protein kinase, putative |
Leishmania mexicana | LmxM.36.0720 | protein kinase, putative,mitogen-activated protein kinase, putative |
Loa Loa (eye worm) | LOAG_13928 | hypothetical protein |
Loa Loa (eye worm) | LOAG_11238 | hypothetical protein |
Mus musculus | ENSMUSG00000063704 | mitogen-activated protein kinase 15 |
Neospora caninum | NCLIV_032840 | Mitogen-activated protein kinase 2, related |
Plasmodium berghei | PBANKA_1013300 | mitogen-activated protein kinase 1 |
Plasmodium falciparum | PF3D7_1431500 | mitogen-activated protein kinase 1 |
Plasmodium knowlesi | PKNH_1327200 | mitogen-activated protein kinase 1, putative |
Plasmodium vivax | PVX_084965 | mitogen-activated protein kinase 1, putative |
Plasmodium yoelii | PY02176 | mitogen-activated protein kinase |
Schistosoma japonicum | Sjp_0300800 | ko:K08293 mitogen-activated protein kinase [EC2.7.11.24], putative |
Schistosoma japonicum | Sjp_0001250 | Putative serine/threonine-protein kinase C05D10.2, putative |
Schistosoma mansoni | Smp_133500 | serine/threonine protein kinase |
Schistosoma mansoni | Smp_134260 | serine/threonine protein kinase |
Schmidtea mediterranea | mk4.000459.06 | Putative serine/threonine-protein kinase |
Trypanosoma brucei gambiense | Tbg972.10.6210 | protein kinase, putative,mitogen-activated protein kinase, putative |
Trypanosoma brucei | Tb927.10.5140 | Mitogen-activated protein kinase 6 |
Trypanosoma congolense | TcIL3000_10_4300 | Mitogen-activated protein kinase 6 |
Trypanosoma cruzi | TcCLB.506007.40 | Mitogen-activated protein kinase 6 |
Trypanosoma cruzi | TcCLB.510295.50 | Mitogen-activated protein kinase 6 |
Toxoplasma gondii | TGME49_233010 | cell-cycle-assocaited protein kinase ERK7, putative |
Theileria parva | TP01_0678 | serine/threonine protein kinase, putative |
Trichomonas vaginalis | TVAG_260190 | CMGC family protein kinase |
Trichomonas vaginalis | TVAG_045770 | CMGC family protein kinase |
Trichomonas vaginalis | TVAG_418770 | CMGC family protein kinase |
Trichomonas vaginalis | TVAG_192740 | CMGC family protein kinase |
Trichomonas vaginalis | TVAG_319710 | CMGC family protein kinase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.5140 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.5140 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.5140 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.5140 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_C05D10.2 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_C05D10.2 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_C05D10.2 | Caenorhabditis elegans | sterile | wormbase |
PBANKA_1013300 | Plasmodium berghei | Dispensable | plasmo |
TGME49_233010 | Toxoplasma gondii | Essentiality uncertain | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | mitogen-activated protein kinase 15 | Compounds | References |
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 37.6% | 295 aa | Compounds | References |
Zea mays | Casein kinase II alpha | 332 aa | 28.7% | 303 aa | Compounds | References |
Rattus norvegicus | Serine/threonine-protein kinase pim-3 | 326 aa | 23.4% | 308 aa | Compounds | References |
Homo sapiens | Cyclin-dependent kinase 1/cyclin B1 | 297 aa | 35.8% | 299 aa | Compounds | References |
Schizosaccharomyces pombe 972h- | Casein kinase II subunit alpha | 332 aa | 27.9% | 298 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 37.6% | 306 aa | Compounds | References |
Rattus norvegicus | Jak1 protein | 210 aa | 26.4% | 178 aa | Compounds | References |
Rattus norvegicus | Mitogen-activated protein kinase 1 | 358 aa | 39.0% | 328 aa | Compounds | References |
Patiria pectinifera | Cdc2 | 300 aa | 34.2% | 304 aa | Compounds | References |
Oryctolagus cuniculus | Cyclin-dependent kinase 4 | 189 aa | 38.2% | 170 aa | Compounds | References |
Rattus norvegicus | MAP kinase p38 alpha | 360 aa | 40.5% | 301 aa | Compounds | References |